Results 21 to 30 of about 617 (209)

Brodalumab

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Brodalumab is a human monoclonal antibody that inhibits interleukin-17 (IL-17) pathway by binding to IL-17 receptor. In clinical trials, a PASI75 response has been achieved in 82-84% of the patients at week 12.
Murat Borlu
doaj   +1 more source

How to treat a patient with psoriatic arthritis and chronic lymphocytic leukemia? [PDF]

Exploration of Musculoskeletal Diseases
A 76-year-old male patient who has been suffering from psoriatic arthritis (PsA) for 15 years was diagnosed with chronic lymphocytic leukemia (CLL) 18 months ago.
Jürgen Braun, Kirsten Karberg, Denis Poddubnyy   +2 more
doaj   +1 more source

Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases

Journal of Translational Autoimmunity, 2021
Background: Interleukin (IL)-17 and T helper 17 (TH17) cells, a distinct subset of CD4+ T cells which promotes the expression of IL-17, mediate host defensive mechanisms to various infections and are involved in the pathogenesis of autoimmune diseases ...
Shintaro Akiyama, Atsushi Sakuraba
doaj   +1 more source

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Современная ревматология, 2020
Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives the data obtained during 52-week follow-up of AS
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva, A. V. Zinkina-Orikhan   +24 more
doaj   +1 more source

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry

Actas Dermo-Sifiliográficas
Interleukin 12/23 inhibitors (IL12/23i) and interleukin 17 and 23 inhibitors (IL17i and IL23i) represent the drug classes with the most favorable expectations for therapeutic response.
R. Rivera-Díaz, A. Quesada, A. Sahuquillo-Torralba, E. Daudén, J.M. Carrascosa, I. Belinchón, F.J. Gomez Garcia, E. Herrera Acosta, D.P. Ruiz Genao, O. Baniandrés Rodriguez, M. Ferrán Farres, P. de la Cueva Dobao, L.R. Fernández-Freire, A. Mateu Puchades, J. Riera-Monroig, J.C. Ruiz Carrascosa, M. Ara Martín, M. Abalde Pintos, M. Roncero Riesco, J.L. Lopez-Estebaranz, C. García-Donoso, I. García-Doval, M. Angel Descalzo   +22 more
doaj   +1 more source

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases [PDF]

Advances in Dermatology and Allergology, 2016
Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for ...
Wasilewska, Anna, Winiarska, Magdalena, Małgorzata Anna Olszewska, Lidia Rudnicka   +3 more
openaire   +2 more sources

COVID-19: a perspective focus on IL-17/Th17

Iatreia, 2022
Interleukin 17 (IL-17)-producing helper T cells (Th17) and IL-17 play an important role in the defense against extracellular bacteria and fungi; however, persistent secretion of IL-17 is also an important component in the pathogenesis of many ...
Úsuga-Úsuga, Franky , García, Luis F., Velásquez-Lopera, Margarita   +2 more
doaj   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

FEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg, Martine Hjeltnes, Josephine Krieger, Joshua E. Elias, Maria Stensland, Kristian Holm, Xiaojun Jiang, Chuki Khangsar, Tuula A. Nyman, Arthur Kaser, Johannes R. Hov, Tom H. Karlsen, Nicole C. Kaneider, Frode L. Jahnsen, Georg Schneditz   +14 more
wiley   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

The Th17 Pathway in Vascular Inflammation: Culprit or Consort?

Frontiers in Immunology, 2022
The involvement of IL-17A in autoimmune and inflammatory diseases has prompted the development of therapeutic strategies to block the Th17 pathway. Promising results came from their use in psoriasis and in ankylosing spondylitis.
Marie Robert, Marie Robert, Pierre Miossec, Arnaud Hot   +3 more
doaj   +1 more source